San Francisco Plastic Surgeon Helps Raise the Bar on Injectable Fillers
On January 5th a new cosmetic dermal filler will be nationally released by the Allergan Corporation. Juvederm, made with Hyaluronic acid, is similar to existing popular fillers such as Restylane and Hylaform. However, there is promise that this filler will be smoother and more comfortable than other Hyaluronic acid fillers currently on the market. Dr. Scott Mosser, a San Francisco-Based Plastic Surgeon is one of the physicians allowed to study this materal on live patients ahead of its release, and he offers his perspective on the benefits of this newly available material.
San Francisco, Calif. (PRWEB) December 29, 2006 -- On January 5, 2007, Juvéderm ™, the latest dermal filler advance from Allergan, Inc. will be released for widespread use as a new facial filler for cosmetic use.
Facial fillers are a variety of medical treatments used to add volume to areas of he face to reduce the appearance of facial aging. Juvéderm is currently the only filler available with the highest concentration of hyaluronic acid and its special formulation process is designed to achieve a smoother result with fewer irregularities on injection.
According to a report on plastic surgery trends, more men and women are forgoing facelifts in favor of injectable wrinkle fillers. The American Society of Plastic Surgeons (ASPS) shows that the number of surgical procedures has dropped by 8 percent from 2000 to 2004, while the number of nonsurgical cosmetic procedures has risen by 36 percent during the same time period. In 2005, there were nearly 11.5 million surgical and nonsurgical procedures performed in the United States. Surgical procedures accounted for nearly 19 percent of the total with nonsurgical procedures making up 81 percent of the total. Out of the top five nonsurgical procedures in 2005, fillers such as Hyaluronic acids (the active ingredient in Restylane and Juvéderm) ranked number three at 1,194,222, up 35 percent from 2004.If the numbers are an indication of the growing trend, Juvéderm may become a new front-runner.
Dr. Scott Mosser, a board certified plastic surgeon in San Francisco, Ca., was one of the physicians chosen to participate in a Juvéderm pilot study earlier this year. "As injectable materials go," says Dr. Mosser, "Juvéderm is one of the easiest to inject, and I'm finding that it's also been easy on my patients in terms of discomfort." Although longevity has yet to be proven in the United States, Dr. Mosser states that he expects the filler to become one of the most requested injectable materials.
Rebecca Bobrowsky, a San Francisco-based Registered Nurse was one of the patients involved in Dr. Mosser's study. Based on her experience, Rebecca considered Juvéderm to be less painful than her prior experience with other materials. "Even in the lip border I had no evidence of swelling, even on the dreaded morning after."
Though Juvéderm's expected launch date is the first week of 2007 there has been a growing demand for the product since the pilot study in late fall of 2006. With less pain, smoother results, and a natural release that aids in longevity, Juvéderm is vying for the position of the filler of choice, with hopes of challenging the other market leaders used to fill lines and wrinkles.
###
|
